cilnidipine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium channel blockers, nifedipine derivatives | 642 | 132203-70-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
has excitatory & inhibitory action on the Ca+ channels in the rabbit basilar artery; structure given in first source; RN given is for (+-) isomer
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Renal impairment | 55.76 | 29.75 | 28 | 916 | 74344 | 46610774 |
| Hepatic function abnormal | 48.06 | 29.75 | 20 | 924 | 34401 | 46650717 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral infarction | 55.69 | 29.67 | 27 | 1492 | 26346 | 29924613 |
| Hyperkinetic heart syndrome | 48.72 | 29.67 | 8 | 1511 | 124 | 29950835 |
| Interstitial lung disease | 44.17 | 29.67 | 31 | 1488 | 60166 | 29890793 |
| Hepatic function abnormal | 43.94 | 29.67 | 27 | 1492 | 41918 | 29909041 |
| Renal impairment | 36.98 | 29.67 | 32 | 1487 | 84152 | 29866807 |
| Echocardiogram abnormal | 35.04 | 29.67 | 8 | 1511 | 724 | 29950235 |
| Stress cardiomyopathy | 33.78 | 29.67 | 9 | 1510 | 1540 | 29949419 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C08CA14 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
| MeSH PA | D002121 | Calcium Channel Blockers |
| MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
| CHEBI has role | CHEBI:35554 | cardiovascular drugs |
| CHEBI has role | CHEBI:35674 | antihypertensive |
| CHEBI has role | CHEBI:38215 | calcium channel blockers |
Drug Use (View source of the data)
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.67 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-gated L-type calcium channel | Ion channel | BLOCKER | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
| Voltage-dependent N-type calcium channel subunit alpha-1B | Unclassified | BLOCKER | IC50 | 6.70 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D01173 | KEGG_DRUG |
| C0378675 | UMLSCUI |
| CHEBI:31399 | CHEBI |
| CHEMBL452076 | ChEMBL_ID |
| DB09232 | DRUGBANK_ID |
| C065927 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5282138 | PUBCHEM_CID |
| 7767 | IUPHAR_LIGAND_ID |
| 6880 | INN_ID |
| 97T5AZ1JIP | UNII |
| 010899 | NDDF |
Pharmaceutical products:
None